Borjas-Ale P, Alonzo-Vázquez F, Palma-Chan A

Idioma: Español
Referencias bibliográficas: 30
Paginas: 128-132
Archivo PDF: 59.59 Kb.

RESUMEN

Objetivo. Conocer la utilidad del esquema con dos inhibidores de la transcriptasa inversa más nelfinavir, en niños con VIH-SIDA. Material y métodos. Doce niños con VIH-SIDA tratados con dos inhibidores de la transcriptasa inversa más nelfinavir. Se registraron datos de exploración física, somatometría, clasificación clínica a su ingreso y cada mes durante seis meses. Se midió la carga viral, la subpoblación linfocitaria, biometría hemática, química sanguínea y pruebas de funcionamiento hepático, al inicio, a los tres y seis meses. El peso, la carga viral, y los linfocitos CD4 del inicio y los seis meses de tratamiento fueron comparados con t pareada y Wilcoxon. Resultados. Los 12 pacientes incluidos tuvieron ganancia significativa en peso y talla y presentaron mejoría tanto clínica como inmunológica. La carga viral tuvo una diferencia no significativa a seis meses del tratamiento. Sin alteraciones relevantes de laboratorio. Conclusiones. Los pacientes tuvieron ganancia en peso y talla estadísticamente significativas. Sin diferencias estadísticas entre la carga viral, las cifras de CD4 y CD8. Sin embargo, hubo decremento de la carga viral e incremento de los CD4, principalmente en niños sin tratamiento previo. El hecho de no encontrar significancia estadística probablemente se deba al tamaño de la muestra y a la heterogeneidad de los pacientes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Roger MF, Thomas PA, Starcher ET et al. Acquired immunodeficiency syndrome in Children: report of the Center for Disease Control National Surveillance, 1982-1985. Pediatrics 1997; 79: 1008-14.

2. Center for Disease Control and Prevention. HIV-AIDS Surveillance. 1995; 7: 1-29.

3. European Collaborative Study Group. Risk Factors for Mother to Child transmission of HIV-1. Lancet 1992; 339: 1007-12.

4. Gabiano CP, Tovo PA, De Martiniano M et al. Mother to Child Transmission of Human immunodeficiency Virus Type 1: risk of infection and correlates of transmission. Pediatrics 1992; 90: 369-74.

5. Raszka WV, Meyer GA Jr, Waecker NJ et al. Variability Pf Serial Absolute and Percent CD4 Lymphocyte Counts in Healthy Children Born to Human Immunodeficiency Virus-1 Infected Parents. Pediatr Infect Dis J 1994; 13: 70-72.

6. Gibb DM, MacDonagh SE, Tookey PA et al. Uptake of Interventions to Reduce Mother to Child Transmission of HIV in the United Kingdom and Ireland. AIDS 1997; 11: F53-F58.

7. Connor EM, Sperling RS, Golber R et al. Reduction of Maternal Infant Transmission of Human Immunodeficiency Virus Type 1 With Zidovudina Treatment. N Engl J Med 1994; 331: 173-1180.

8. Domachowske JB. Pediatric Human Immunodeficiency Virus Infection. Clin Microbiol Rev 1996; 9: 448-68.

9. Center for Disease Control and Prevention. Recommendations of The U.S. Public Health Service Task Force on the Use of Zidovudina to Reduce Perinatal Transmission of Human Immunodeficiency Virus. MMWR 1994; 43 (No. RR-11).

10. Center for Disease Control and Prevention. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected With HIV-1. For Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. MMWR 1998; 47 (No. RR-2).

11. Working Group on Antiretroviral Therapy, National Pediatric HIV Resource Center. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. MMWR 2001: 1-70.

12. Perelson AS, Newmann AU, MacKuwitz M, Leonard JM, Ho DD. HIV-1 Dynamics In Vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-86.

13. Havlir DV, Richman DD. Viral Dynamics of HIV Implications for Drug Development and Therapeutic Strategies. Ann Intern Med 1996; 271: 1582-86.

14. Mellors JW, Kingsley LA, Rinaldo CR et al. Quantification of HIV-1 RNA in Plasma Predicts Outcome After Seroconversion. Ann Intern Med 1995; 122: 573-79.

15. Delaware C, Bungard M, Mayaux MJ et al. HIV-1 RNA Detection in Plasma for the Diagnostic of Infection in Neonates. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997; 15: 121-25.

16. Stein DS, Lyles RH, Neil MH et al. Predicting Clinical Progression of Death in Subjects With Early-Stage Human Immunodeficiency Virus Infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and B2- microglobulin. J Infect Dis 1997; 176: 1161-67.

17. Katzenstein TL, Pedersen C, Nielson C et al. Longitudinal Serum HIV-RNA Quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996; 10: 167-73.

18. Butler KM, Husson RN, Balis M et al. Dediexyinosine in Children with Symptomatic Human Immunodeficiency Virus Infection. N Engl J Med 1991; 324: 137-44.

19. Lewis LL, Venzon D, Church LA et al. Lamivudine in Children with Human Immunodeficiency Virus Infection: a phase I/II study. J Infec Dis 1996; 174: 16-25.

20. Kline MW, Dukle LM, Church JA et al. A Phase I/II Stavudine (d4T) in Children with Human Immunodeficiency Virus Infection. Pediatrics 1995; 96: 247-52.

21. Kline MW, Van Dyke RB, Lindsey JC et al. A Randomized Comparative Trial of Stavudine (d4T) versus Zidovudine (ZDV, AZT) in Children with Human Immunodeficiency Virus Infection. Pediatrics 1998; 101: 214-20.

22. Center for Disease Control and Prevention. Guidelines for the use of Antiretroviral Agents in Pediatric HIV Infection. MMWR 1998; 47 (No. RR-4): 1-45.

23. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease Inhibidor Therapy in Children with Perinatally Acquired HIV Infection. AIDS 1997; 11: F107-F11.

24. Luzuriaga K, Bryson I, Krogstad P et al. Combination Treatment With Zidovudine, Didanosine, and Nevirapine in Infants With Human Immunodeficiency Virus Type 1 Infection. N Engl J Med 1997; 336: 1343-9.

25. Funk MB, Linde R, Wintergerst U et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS (England), 1999; 13: 1653-8.

26. Starr SE, Fletcher CV, Spector SA et al. Combination therapy with efavirenz, nelfinavir and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type I. Pediatric AIDS Clinical Trials Group 382 Team. N Eng J Med 1999; 341: 1874-81.

27. Pai VB, Nahata MC. Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother (United States) 1999; 33: 325-39.

28. Jarvis B, Faulds D. Nelfinavir. A review of this therapeutic efficacy in HIV infection. Drugs (New Zealand) 1998; 56: 147-67.

29. Project Inform. Information, inspiration and advocacy for people living with HIV/AIDS. 2000: 1-6.

30. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs (New Zealand) 2000; 59: 581-620.